| Similar Articles |
|---|
 |
National Defense
November 2005
Margaret Davidson |
Biodefense Experts: Vaccines `At a Crossroads' Many of the companies seeking government funds for biodefense work are small firms with no experience in bringing a drug to market. And they face a significant challenge.   |
National Defense
June 2007
Breanne Wagner |
Agencies Scramble to Create Vaccine Market Defense and Homeland Security are pursuing disparate vaccination programs to combat different needs for military and civilian populations. |
National Defense
November 2010
Eric Beidel |
To Counter Bioterrorism, The Key is Boosting Immunity That's why Texas A&M University researchers are investigating ways to arm Americans against attacks involving toxins, viruses and bacteria. |
National Defense
July 2009 |
Readers Sound Off on Recent Stories 7 Deadly Myth article draws comment. |
Wired
September 2002
Amanda Griscom |
Take These Genes and Call Me in the Morning Gene vaccines may be relatively new, but they're the logical outgrowth of two familiar strands of medical science. |
Salon.com
October 9, 2001
Suzy Hansen |
Plague fears A bioterrorism expert talks about the wicked ways of anthrax and the even deadlier potential scourge of smallpox... |
Bio-IT World
September 16, 2004
Zachary Zimmerman |
The Dark Side of Project BioShield Despite the uncertainties, an estimated 100 biopharma companies are developing anti-terror technologies. But they should examine both sides of Project BioShield before considering product development. |
National Defense
June 2010
Grace V. Jean |
Research Challenge: How to Defend Against Still-Undefined Chemical, Biological Attacks Military scientists are often criticized for not working fast enough and for not pushing technologies into the field more expeditiously. Those working in chemical and biological sciences are no exception. |
National Defense
March 2005
Sandra I. Erwin |
Pentagon Redirects Priorities In Chemical-Biological Defense The Pentagon will broaden the scope of its chemical and biological defense programs, in an effort to prepare for future domestic emergencies, officials say. |
Bio-IT World
April 15, 2003
James Golden |
Sequence Signatures and Homeland Security The bio-IT community has a unique opportunity to contribute to national biodefense. |
Scientific American
April 10, 2006
Christine Soares |
Turning Yellow Yellow fever shot confers long-lasting immunity, a trait that medical researchers hope to transfer to other kinds of vaccines. |
National Defense
August 2005
Joe Pappalardo |
Pentagon Spurs its Biological And Chemical Defense Programs The Pentagon is trying to buttress the military's defensive posture against biological and chemical weapons by focusing on the development of advanced vaccines and improved therapeutics. A surge in money is fueling this effort. |
National Defense
March 2013
Stew Magnuson |
Chemical-Biological Defense Office To Kick Off Dozens of New Programs The previous decade has seen little in terms of advancement of nuclear-radiological detection devices, and there will be a new push to update them. |
Searcher
March 2002
Eva Perkins |
Bioterrorism Resources on the Internet: A Primer What is bioterrorism? Which organizations and governmental agencies publish in this area? Using the power of the beloved Internet, one can easily and quickly access a wealth of information. Here's how to do it... |
Salon.com
December 15, 2000
Arthur Allen |
Warming to malaria With fears mounting that global climate change may cause the dreaded disease to spread, scientists turn their attention to vaccine research... |
National Defense
September 2004
Joe Pappalardo |
Security Beat Vaccine Stockpiles Now Required by Law... Commission: Military Had No Warning During 9/11... Simulated Agent Mimics Bio-Terror Weapons... Cyber-security Hampered by Lack of Attention... |
Bio-IT World
June 15, 2003
Malorye Branca |
A View to a Kill Genomics, bioinformatics, and novel laboratory techniques are converging to boost vaccine research against a new wave of emerging diseases, natural and man-made. Now, will in silico modeling ramp up sufficiently to further speed vaccine discovery? |
Scientific American
November 2008
John Dudley Miller |
Postal Anthrax Aftermath: Has Biodefense Spending Made Us Safer? The Anthrax attacks in 2001 led to a massive increase in biodefense funding, which critics claim has done more harm than good |
Wired
January 2003
Richard Martin |
Testing the First AIDS Vaccine Medical establishment, government, and Genentech be damned -- Don Francis has never stopped believing. Now he's about to finish testing the first human AIDS vaccine. |
BusinessWeek
October 24, 2005
John Carey |
New Vaccines For A Pandemic Using DNA, vast amounts of flu vaccine could be made quickly. But will the drugs work? |
Scientific American
November 2008
Jessica Wapner |
Cancer Vaccine: Looking Beyond Tumor Size Proponents see hope in changing cancer vaccines' bad reputation |
Pharmaceutical Executive
December 1, 2005
Anthony Tao |
The Avian Few: Is it Too Late for Pharma to Re-enter the Vaccine Fray? Small profit margins and high litigation risks drove most companies out of the vaccine business decades ago. As a possible pandemic looms, pharma re-enters the fray. Is it too late? |
American History
Margaret Davidson |
American Biowarrior A pioneer in America's biological weapons program during World War II, the unassuming Dr. Ira Baldwin was critical to the development of methods that made large-scale, safe production of the deadly toxins possible. |
Fast Company
June 2015 |
Meet Ebola's Soft-Spoken, Plant-Loving Arch Nemesis A professor at Arizona State University, Arntzen is considered the godfather of a growing field of research sometimes called "pharming": engineering plants to produce specialized vaccines and other drugs. |
Popular Mechanics
September 2006
Ben Harder |
Seeking Immunity Pathogens like West Nile virus show no respect for borders. But a new class of vaccines may soon keep them in check. |
American Family Physician
May 1, 2003
O'Brien & Halverson |
Recognition and Management of Bioterrorism Infections Familiarity with the infectious agents of highest priority can expedite diagnosis and initial management, and lead to a successful public health response to such an attack. |
HBS Working Knowledge
March 1, 2004
Martha Lagace |
Injecting New Life into the Vaccine Industry Vaccines for preventable diseases save millions of lives every year, yet as an industry, the vaccine business suffers a host of ailments, the CEO of Merck & Co. contends. |
Popular Mechanics
February 2007
Simon Cooper |
North Korea's Suspected Biochemical Weapons: Breakdown Compared to nukes, biological and chemical agents offer mass destruction "on the cheap," argues Michael Stebbins of the Federation of American Scientists. Below, a sampling of Kim Jong Il's toxic arsenal. |
Salon.com
October 3, 2001
Chris Colin |
Poison on the mind Is panic the right response to the specter of bioterrorism? |
Salon.com
October 3, 2001
Pamela Weintraub |
Be prepared? Taking precautions against bioterrorism may not be as futile as you think... |
Mother Jones
Jan/Feb 2002
Bill Hogan |
A Biodefense Boondoggle As pharmaceutical companies line up for multimillion-dollar contracts to make bioterrorism vaccines, some question whether the industry is up to the job... |
National Defense
June 2009
Erwin & Magnuson |
7 Deadly Myths About Weapons of Terror Seven noteworthy misconceptions associated with weapons of terror. |
National Defense
October 2015
Stew Magnuson |
Chemical-Biological Program Speeds Up Acquisition Process Whenever there is a crisis somewhere in the world related to chemical, biological or radiological weapons or accidents, "the first phone call comes to us," said Carmen Spencer, joint program executive officer for chemical and biological defense. |
Bio-IT World
November 14, 2003
Jason B. Lee |
Profiting from the BioShield How can software developers ensure a share of the tremendous biodefense funding available to bio-IT companies -- and what are the risks? |
Chemistry World
August 20, 2014
Maria Burke |
Doctors turn to experimental Ebola treatments The emergency use of an experimental medicine is highly unusual, but the WHO has declared the Ebola outbreak a public health emergency of international concern. |
The Motley Fool
May 22, 2007
Mike Havrilla |
An Emergent Opportunity The vaccine developer guided for revenue growth of 10% to 15% for this year. Emergent also has a strong balance sheet, with more than $67 million in cash and investments. Investors, take note. |
Geotimes
May 2007
Megan Sever |
The Plague: Could It Happen Again? Centuries ago, plague was brought about by the expansion of global travel at the same time climate changed. Given the extent of globalization today, and the fact that the climate is changing, health officials and the public wonder if there is a risk of history repeating itself. |
BusinessWeek
September 23, 2010
Rob Waters |
Stem Cells That Save Big Pharma a Bundle Drugmakers hope to save big by using stem cells to test drugs for dangerous side effects long before costly human trials are needed. |
Salon.com
October 3, 2001
Andrew Leonard |
The invisible nightmare Biological weapons are not that hard to produce, says a sober new book written before Sept. 11 -- and they're getting easier all the time... |
Pharmaceutical Executive
October 1, 2014
Jill Wechsler |
Ebola Crisis Challenges Pharma R&D Companies gain support and pressure to deliver new treatments for spreading outbreak. |
Pharmaceutical Executive
July 3, 2007
Jill Wechsler |
Washington Report: Vaccines for Everyone New vaccines can be good business and a huge boon to public health. But the challenge is to establish prices that ensure global access, and to bring necessary medications to third-world countries. |
BusinessWeek
October 25, 2004
John Carey |
A Booster Shot For Vaccines New technology could speed the development of vaccines and keep the medicine chest stocked. |
Salon.com
March 8, 2001
Amy Standen |
Ready for some lockjaw? There's no profit in the tetanus vaccine business, so a rare and hideous disease may soon strike more Americans... |
Chemistry World
September 26, 2007
Victoria Gill |
HIV Vaccines 'Will Not Work' Just days after US drug firm Merck revealed its leading HIV vaccine candidate had flopped in clinical trials, a leading immunologist has predicted that many other vaccines in the pipeline will also fail because their design is similarly flawed. |
BusinessWeek
April 30, 2007
Catherine Arnst |
Teaching The Body To Fix Itself Cancer vaccines still in trial stages may be able to prolong life with few side effects, but the FDA has yet to be convinced. |
AskMen.com
Jacob Franek |
4 Future Plagues What future plagues await us? Let's have a look. |
Pharmaceutical Executive
February 1, 2009
Joanna Breitstein |
Vaccines for All The world is suffering. But just over the horizon is a new access equation that could speed innovative vaccines to where they're needed most. |
Chemistry World
September 29, 2014
Rebecca Trager |
White House tightens oversight of dangerous studies The White House has intensified federal oversight of research involving dangerous pathogens with new safety rules for universities and other research institutions that carry out such work. |
National Defense
June 2010
Grace V. Jean |
To Counter Weapons of Mass Destruction, U.S. Reaching Out To International Partners U.S. officials believe that terrorists aspire to build bio-weapons. The White House is also expanding collaborative efforts with international partners to help prevent such attacks. |
Chemistry World
July 2010
Hayley Birch |
Special Report: Health breakthroughs of the decade New discoveries have been made with cancer vaccines, genomics, statin drugs, allosteric modulators, and RNA interference during the last decade. |
